Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pseudomyxoma Peritonei × Tacrolimus × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myelodysplastic Syndromes 94 Leukemia, Myeloid, Acute 94 Precursor Cell Lymphoblastic Leukemia-Lymphoma 80 Leukemia 66 Hodgkin Disease 60 Lymphoma, Non-Hodgkin 59 Lymphoma 58 Multiple Myeloma 57 Leukemia, Lymphocytic, Chronic, B-Cell 57 Myeloproliferative Disorders 44 Graft vs Host Disease 42 Lymphoma, Follicular 41 Hematologic Neoplasms 39 Leukemia, Myelomonocytic, Chronic 38 Leukemia, Myeloid, Accelerated Phase 38 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 38 Lymphoma, Large B-Cell, Diffuse 37 Lymphoma, Mantle-Cell 36 Leukemia, Myeloid, Chronic-Phase 34 Primary Myelofibrosis 33 Burkitt Lymphoma 33 Lymphoma, B-Cell, Marginal Zone 32 Congenital Abnormalities 32 Blast Crisis 29 Neoplasms, Plasma Cell 27 Lymphoma, Large-Cell, Immunoblastic 26 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 20 Myelodysplastic-Myeloproliferative Diseases 19 Waldenstrom Macroglobulinemia 18 Lymphoma, T-Cell, Cutaneous 18

Interventions

Mitomycin 3 Hyperthermic Intraperitoneal Chemotherapy 2 Capecitabine 2 tislelizumab 1 molgramostim 1 irinotecan sucrosofate 1 cryoprecipitate coagulum 1 Tacrolimus 1 Surveys and Questionnaires 1 Specimen Handling 1 Sirolimus 1 Radiosurgery 1 Psychiatric Rehabilitation 1 Pharmacogenomic Testing 1 Oxaliplatin 1 Nivolumab 1 Methods 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lansoprazole 1 Ipilimumab 1 Gemcitabine 1 Fluorouracil 1 Floxuridine 1 Early Intervention, Educational 1 Cytoreduction Surgical Procedures 1 Clarithromycin 1 Carboplatin 1 CTLA-4 Antigen 1 Bromelains 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡